As the COVID-19 pandemic continues and in-person activities and travel remain restricted, FDA has been making pharma inspection decisions using rules and policies that are not understood by the industry. The decisions can be a source of consternation for those hoping to be inspected—for example, as part of a new drug approval or for clearing an Official Action Indicated (OAI) status at a manufacturing site.

[Related: How can you become a leader in Quality at your organization? Find out by downloading our latest report here.]

The Current Pharma Quality Landscape banner

In some cases, the agency has let an action date lapse and taken no action.  In other cases, it has chosen to schedule an inspection after approving a Biologic License Application (BLA) rather than as a prerequisite or to perform a “desk review” of documentation in lieu of an in-person inspection to approve a manufacturing site.

At FDLI’s Enforcement, Litigation, and Compliance Conference held virtually in December 2020, Parexel Technical Vice President Philip Crooker shared his company’s insights into the current inspection landscape, including details it has learned from its clients regarding FDA inspection alternatives they are experiencing.

“Along the spectrum of clients that we work with that range from very small biotech to what we would call sophisticated enterprise organizations—like Pfizer—a lot of this is determined on a very case-by-case specific basis that I think frustrates people,” Crooker commented.  “But FDA is trying to develop a policy in the midst of a pandemic that is moving quickly, changing rapidly, and causing a variety of different situations.”

FDA Inspection Flexibility

Crooker explained that he has seen a continuum of flexibility regarding the different types of FDA inspections.  Based on his experience, the agency’s inspections can be roughly categorized on a sliding scale from most to least flexible (Figure 1).

FDA Internal Guidance on Pharma Inspections
FIGURE 1 | FDA Internal Guidance on Pharma Inspections

“This slide shows a continuum of what we have noticed in terms of flexibility, with certain types of inspections, as you go from left to right,” Crooker said.  “Preapproval or pre-license inspections are situations where we have seen more flexibility and the least amount of flexibility on routine surveillance.  And I will put for-cause inspections to clear warning letters in that category as well.”

FDA’s Compliance Programs—some of which are cited in Figure 1 by program number—provide instructions to FDA personnel for conducting activities to evaluate industry compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other laws administered by the agency.

FDA publishes Compliance Program Guidance Manuals (CPGMs) covering the following areas:

  • Biologics (CBER)
  • Bioresearch Monitoring (BIMO)
  • Devices/Radiological Health (CDRH)
  • Drugs (CDER)
  • Food and Cosmetics (CFSAN)
  • Veterinary Medicine (CVM)

The Field Management Directives (FMD) Manual is the primary vehicle for distributing procedural information/policy on the management of Office of Regulatory Affairs (ORA) field activities.  The manual is issued on the authority of the Associate Commissioner for Regulatory Affairs (ACRA) and is intended as internal guidance directed to field managers.

The titles of the CPGM and FMD documents cited above are shown below.  Links are provided at the end of this article.  It is recommended that pharma manufacturing companies be familiar with the ones that are applicable to them.

FDA Inspection Alternatives Experienced

Pharma companies have experienced a variety of FDA inspection alternatives that range from taking no action on impending inspections/decisions to waiving a preapproval or pre-license inspection or choosing to inspect remotely.  “There have been some very broad parameters that FDA has placed on what constitutes a mission-critical inspection or a mission-critical application or drug,” Crooker commented.  Some of these scenarios are listed in Figure 2, with additional detail following.

FIGURE 2 | FDA Inspection Alternatives

Removing a site from a supply chain

If a supply chain is set up in a way such that it contains a problematic site—for example, one with an objectionable FDA site classification—and that site can be removed from the supply chain in the application, it can allow FDA to grant an approval with the remaining sites that have an acceptable FDA classification.  “That is one of the simplest solutions that we have seen” to increase the chances of a successful inspection, Crooker commented.

Choosing to schedule a post-approval audit inspection

One publicly available example is illustrated by Biologic License Application (BLA) 761156 filed by Novo Nordisk for Sogroya (Somapacitan-beco, 10 mg/1.5 mL prefilled pen) for “replacement of endogenous growth hormone in adults with growth hormone deficiency.”  The BLA “Summary Review” published by FDA’s Center for Drug Evaluation and Research (CDER) included the following (Figure 3):

Figure 3 Cross-Discipline Team Leader Review
FIGURE 3 | Cross-Discipline Team Leader Review

It is worth noting that the document is dated August 6, 2020, which is before the PDUFA Goal Date of 28 August 2020.  It includes a recommendation for approval.

Included in the 51-page document are the following sections:

  • Benefit-Risk Assessment
  • Background
  • Product Quality
  • Nonclinical Pharmacology/Toxicology
  • Clinical Pharmacology
  • Clinical Microbiology
  • Clinical/Statistical Efficacy
  • Safety
  • Advisory Committee Meeting
  • (Section and name redacted using code (b)(4))
  • Other Relevant Regulatory Issues
  • Labeling
  • Postmarketing Recommendations
  • Recommended Comments to the Applicant

In the Product Quality section, it states (boldface added for emphasis), “During the review of the application, Dr. Ondeck noted that Novo Nordisk A/S, which is responsible for major activities related to the manufacturing and/or development of the final combination involving the device constituent part, has never been inspected.  He indicates that the drug is not an emergency use product, the device is a typical pen injector, and it does not include vulnerable population, thus, the inspection is necessary. In addition, the Applicant already manufactures the identically designed device in other sites. However, the reviewer states the inspection can be done post-approval based ‘on given the risk of the product/user and lack of complexity of the device manufacturing processes.’  This issue should not affect approvability.”

Conducting a Desktop Assessment

The CDER Office of Pharmaceutical Quality (OPQ) made available NDA #213227 Product Quality Review, Integrated Quality Assessment document, an application for a new drug, Copper Cu-64 dotatate.  It is a positron emitting isotope of copper to be manufactured by Curium US LLC at its Maryland Heights, MO site. The NDA was approved without an in-person inspection of the facility.

A preapproval inspection was requested by Curium US.  However, in its place a “desk review” as permitted under the 2012 FDA Safety and Innovation Act (FDASIA) section 706, which allows the agency to obtain certain records and other information from a drug manufacturer in lieu of or in advance of an inspection, was conducted as shown in Figure 4 (taken directly from the NDA document):

Figure 4 Desk Review Pre-Approval Inspection
FIGURE 4 | Desk Review

Letting an action date lapse with no action

Crooker provided an example of a situation in which what appeared to be a promising new drug product was not acted on by FDA prior to its PDUFA action date.

In December 2019, Bristol-Myers Squibb (BMS) announced that the pivotal study of lisocabtagene maraleucel (liso-cel), an investigational CD19-directed CAR T-cell therapy for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies, “had met its primary and secondary endpoints while demonstrating durable responses.”  The company said it planned to submit a BLA by the end of the year.

Nearly a year later, on November 16, 2020, BMS announced that FDA had informed it that agency review of the BLA for liso-cel will not be completed by the PDUFA action date of November 16, 2020.

FDA said that it was unable to conduct an inspection of a third-party manufacturing facility in Texas during the current review cycle due to travel restrictions related to the COVID-19 pandemic.  Therefore, the agency is deferring action on the application until the inspection can be completed.  The application remains under review.  FDA did not provide a new anticipated action date.

“That was a product that seemed to have a significant number of mission critical indicia,” Crooker said, meaning that it had indications that matched what one would suppose would put it near the top of the agency’s list for priority approval.  “Their application is now in a holding pattern until they have a domestic inspection that is completed for a facility in Texas.”

Recommendations for Manufacturers

Crooker provided some recommendations that his firm shares with clients to help guide them through the current inspection landscape and provide suggestions on how they might work with FDA to get their inspections accomplished (Figure 5).

Figure 5 Recommendations for Manufacturers
FIGURE 5 | Recommendations for Manufacturers

“The first point here is important,” Crooker maintained.  “It is early advocacy.  We have seen applicants who get a communication from FDA during the review period of an application that essentially says, ‘We cannot inspect facility X, Y, or Z because of the travel restrictions.  Please acknowledge.’”

He noted that there is a difference between acknowledging receipt of the letter and acknowledging that what it says is an acceptable posture from FDA.  “Some of the receiving companies may not be as sophisticated—they may be foreign; they may be smaller; they may not be U.S.-based. Sometimes they get surprised by that. And that is when they contact us.”

“Your advocacy,” he stressed, is “extremely important,” particularly when it comes to pre-license or pre-approval inspections.  “It should begin early, even prior to submission of the application, as a component of your discussions with FDA and your pre-submission meetings.”

“They may take a very neutral stance,” the Parexel Vice President said.  “They may tell you there are a number of factors that have to be weighed.  That does not stop the applicant from proposing a number of different approaches along a spectrum that can satisfy all parties so that the application is not delayed due to an inspection.”

There has been some correspondence from various trade groups such as PhRMA, BIO, AAM, and the PABO group on the inspection topic.  “You can certainly align yourself with those,” Crooker said.

There are some constraints about records in advance or in lieu of inspection.  “Stephanie [Haggerty] mentioned products that are prepared by aseptic processes.  MHRA has had recent comments in public forums that it is their policy that a drug that is aseptically processed is just not going to be eligible for a remote inspection.  That is where they have chosen to draw the boundaries for their policy, matching the mission-critical indicia.”

He pointed out that foreign agencies are developing their own guidelines around remote assessments. “If you are operating in a global environment, or if you want to align your approach and your thinking with agencies that are also communicating with FDA on this topic,” referring to the EMA Guidance related to Good Manufacturing Practice (GMP)/Good Distribution Practice (GDP) and Plasma Master File (PMF) distant assessments “can help align and draw some of the criteria more narrowly so that you have some more confidence in some of the proposals that you are submitting to FDA.”

Resource Links

CPGM 7346.832 (Pre-Approval Inspections/Investigations)
CPGM 7346.843 (Post Approval Audit Inspections)
CPGM 7356.002 (Drug Manufacturing Inspections)
CPGM 7356.002A (Sterile Drug Process Inspections)
CPGM 7356.002B (Drug Repackers and Relabelers)
CPGM 7356.002F (Active Pharmaceutical Ingredients)
CPGM 7356.002M (Inspections of Licensed Biological Therapeutic Drug Products)
CPGM 7356.021 (Drug Quality Reporting System (DQRS) (MedWatch Reports); NDA Field Alert Reporting (FARs))
FMD-17 (Field Management Directive-17: Field Assignment Issuances Guidelines for Headquarters Offices)
Biologic License Application (BLA) 761156 Summary Review
New Drug Application (NDA) 213227 Product Quality Review, Integrated Quality Assessment
EMA Guidance related to GMP/GDP and PMF distant assessments

[Related: Our latest FREE report contains four articles by Jerry Chapman focusing on different areas of pharmaceutical quality. Download it today.]

The Current Pharma Quality Landscape banner

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.